GC Biopharma's LG CNS pact puts Green Cross stock on earnings watch

Published on 10/20/2026 at 00:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell 15.8 percent to KRW 421.20 billion. Green Cross stock faces November 3 results and a KRW 33.60 billion profit forecast.

Operations and earnings at a glance

GC Biopharma set a 2030 automation target with LG CNS on October 14, 2026.
Second-quarter revenue fell 15.8 percent to KRW 421.20 billion in 2026.
Green Cross had a KRW 1.5 trillion market capitalization as of October 19, 2026.

Green Cross, KR7006280002, Illustration mit AI erstellt.

Green Cross (ISIN KR7006280002) is preparing a smart-factory expansion with LG CNS while its second-quarter earnings remain under pressure. ATS View reported that the companies are targeting automated production by 2030 in an October 14, 2026 update. The investment story now combines manufacturing efficiency with a sharp earnings reset.

Automation plan targets 2030

The LG CNS cooperation covers artificial intelligence tools for production and quality management. The October 14 plan gives Green Cross a concrete operating target, but the financial payoff remains tied to execution across its Korean facilities.

The company also advanced its GC4006A mRNA vaccine program. According to Korea Biomedical Review on September 21, 2026, South Korea approved the Phase 2 trial application on September 11, with first dosing planned within 2026 and a Phase 3 application targeted for 2027.

What will the next report test?

The immediate test is whether delayed influenza vaccine revenue and expanding Aliglo sales can improve profitability. MoneyToday reported on October 11, 2026, that analysts projected third-quarter revenue of KRW 588.40 billion, down 3.5 percent year over year, alongside operating profit of KRW 33.60 billion, up 15.1 percent.

The contrast with the second quarter is substantial. Seoul Economic Daily reported on October 2, 2026, that revenue fell 15.8 percent to KRW 421.20 billion and operating profit dropped 93.7 percent to KRW 1.73 billion. First-half operating profit fell 61.9 percent to KRW 13.50 billion, while operating cash flow was a net outflow of KRW 4.80 billion.

Dates and market context

The next dated event is November 3, 2026, when GC Biopharma is scheduled to report third-quarter results, according to Investing.com. That release will show whether the forecast rebound has reached reported earnings.

Chronology points to three measurable milestones: GC4006A received Phase 2 approval on September 11, 2026; second-quarter revenue reached KRW 421.20 billion on October 2, 2026; and the LG CNS automation plan set a 2030 target on October 14, 2026. Together, they frame a company balancing pipeline development with near-term margin pressure.

Green Cross stock and the next report

Green Cross was last quoted at KRW 130,700 on the Korea Exchange on October 19, 2026 at 3:30 p.m. KST. The quote was 22.47 percent above the 52-week low of KRW 105,900 and 28.89 percent below the 52-week high of KRW 183,800. The market capitalization was KRW 1.5 trillion as of October 19, 2026.